| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474756 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US6143274 | BRACCO | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US5846519 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2015
(8 years ago) | |
Prohance is owned by Bracco.
Prohance contains Gadoteridol.
Prohance has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Prohance are:
- US5474756
- US6143274
- US5846519
Prohance was authorised for market use on 16 November, 1992.
Prohance is available in injectable;injection dosage forms.
Prohance can be used as contrast agent for mri.
The generics of Prohance are possible to be released after 08 December, 2015.
Drugs and Companies using GADOTERIDOL ingredient
Market Authorisation Date: 16 November, 1992
Treatment: Contrast agent for mri
Dosage: INJECTABLE;INJECTION
More Information on Dosage
PROHANCE family patents
